Abstract
Chemoradiotherapy regimens for stage III non-small-cell lung cancer (NSCLC) require ongoing evaluation. This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. Consecutive eligible patients received two cycles of oral vinorelbine 50 mg/m day 1 (D1), day 8 (D8) and intravenous cisplatin 50 mg/m D1 and D8 in a 21-day cycle. Chemotherapy was administered concurrently with radiotherapy at 60 Gy in 30 fractions, 2 Gy/fraction to the isocentre, all fields treated daily, 5 days a week over 6 weeks using 10 MV photons and three-dimensional conformal radiotherapy. The primary endpoint was to evaluate the progression-free survival (PFS). The secondary end points were safety, response rates and overall survival (OS). Forty-three eligible patients with stage III NSCLC - comprising 21 squamous cell carcinoma, 18 adenocarcinoma and four large cell carcinoma - were studied. Four patients did not complete the treatment. By intention-to-treat analysis, 25% showed a partial response and 65% had stable disease. None achieved a complete response. Of the 39 patients who completed protocol-sp...Continue Reading
References
Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Dec 1, 1992·AJR. American Journal of Roentgenology·S D DavisC I Henschke
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DepierreJ Clavier
Jun 1, 1996·Cancer·J P Pignon, L A Stewart
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J JassemA Depierr
Feb 2, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MartyC Puozzo
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everett E VokesMark R Green
Oct 29, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J JassemF Lefresne
Mar 22, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M De LenaJ Gasmi
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Gordon OkawaraUNKNOWN Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care
Sep 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Maciej KrzakowskiPhilippe David
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaUNKNOWN US Oncology
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne AupérinJean-Pierre Pignon
Dec 18, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Renaud DescourtUNKNOWN GFPC VINCR Team
Citations
Sep 30, 2016·Scientific Reports·Shan Xian GuoFang Fang Tou
Mar 2, 2017·World Journal of Clinical Oncology·Stephanie M YoonMark Hallman
Mar 2, 2016·Therapeutic Advances in Medical Oncology·Robert E HurstMichael A Ihnat
Sep 4, 2018·Expert Review of Anticancer Therapy·Paul LesueurChristos Chouaid
Apr 27, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Costa RivasJ Casal Rubio
Aug 26, 2017·Asia-Pacific Journal of Clinical Oncology·Harminder TakharMichael P Brown